Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis

Liver International

Volumn 31, Issue 9, 2011, Pages 1406-1415

  Gundling, Felix ^a   Schmidtler, Fabian ^b   Hapfelmeier, Alexander ^c   Schulte, Benjamin ^a   Schmidt, Thomas ^a   Pehl, Christian ^d   Schepp, Wolfgang ^a   Seidl, Holger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM BOGENHAUSEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Vilsbiburg Hospital   (Germany)

Author keywords

Calprotectin; Cirrhosis; Hepatic encephalopathy; Spontaneous bacterial peritonitis

Indexed keywords

CALGRANULIN;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CONTROLLED STUDY; DISEASE SEVERITY; FECES LEVEL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; SENSITIVITY AND SPECIFICITY;

AGED; BACTERIAL TRANSLOCATION; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FECES; FEMALE; GERMANY; HEPATIC ENCEPHALOPATHY; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERITONITIS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80052531683     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02577.x     Document Type: Article

References (35)

1. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-72.
2. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55: 1-12.
3. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
4. Bauer TM, Schwacha H, Steinbrückner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002; 97: 2364-70.
5. Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003; 98: 1362-70.
6. Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996; 41: 552-6.
7. Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010; 53: 849-55.
8. McPhail MJ, Bajaj JS, Thomas HC, et al. Pathogenesis and diagnosis of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010; 4: 365-78.
9. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
10. D' Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease?Am J Gastroenterol 2008; 103: 2007-14.
11. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369, 11pp.
12. Hofmann WP, Rädle J, Moench C, et al. Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests. Z Gastroenterol 2008; 46: 1283-9.
13. Asrani SK, Kim WR. Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. Curr Opin Gastroenterol 2010; 26: 209-13.
14. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002:35: 716-721.
15. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-66.
16. Romero-Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007; 45: 879-85.
17. Poullis A, Foster R, Northfield TC, et al. Fecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 675-81.
18. Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics 2008; 64: 1263-9.
19. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the internatinal ascites club. Gut 2005:54: 718-725.
20. Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18: 756-62.
21. Montalto M, Curigliano V, Santoro L, et al. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol 2007; 102: 132-6.
22. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009; 41: 56-66.
23. Shitrit AB, Braverman D, Stankiewics H, et al. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum 2007; 50: 2188-93.
24. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-9.
25. Homann C, Christensen E, Schlichting P, et al. Ascites fluid and plasma calprotectin concentrations in liver disease. Scand J Gastroenterol 2003; 38: 415-20.
26. Homann C, Garred P, Graudal N, et al. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology 1995; 21: 979-85.
27. Homann C, Garred P, Graudal NA, et al. Plasma calprotectin. A new prognostic marker of survival in alcoholic liver cirrhosis. Ugeskr Laeger 1996; 158: 2980-4.
28. Yagmur E, Schnyder B, Scholten D, et al. Elevated concentrations of fecal calprotectin in patients with liver cirrhosis. Dtsch Med Wochenschr 2006; 131: 1930-4.
29. Montalto M, Gallo A, Ferrulli A, et al. Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. Eur J Gastroenterol Hepatol 2011; 23: 76-80.
30. Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM 2006; 8: 433-5.
31. Miese F, Kircheis G, Wittsack HJ, et al. (1)H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. AJNR Am J Neuroradiol 2006; 27: 1019-102.
32. Kircheis G, Fleig WE, Görtelmeyer R, et al. Assessment of low-grade hepatic encephalopathy: a critical analysis. J Hepatol 2007; 47: 642-50.
33. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-48.
34. Koulaouzidis A, Bhat S, Saeed AA. Spontaneous bacterial peritonitis. World J Gastroenterol 2009; 15: 1042-9.
35. Poullis A, Foster R, Mendall MA, et al. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specifity. Eur J Gastroenterol Hepatol 2003; 15: 573-4.